Literature DB >> 21835147

IDO in human gut graft-versus-host disease.

Philippe Ratajczak1, Anne Janin, Régis Peffault de Larour, Lisa Koch, Brigitte Roche, David Munn, Bruce R Blazar, Gérard Socié.   

Abstract

Although rodent graft-versus-host disease (GVHD) models have suggested that indoleamine 2,3-dioxygenase (IDO) is a critical regulator of gastrointestinal GVHD, parallel human studies on IDO expression have not been reported. IDO expression was assessed in 20 patients who underwent duodenal biopsy. IDO was upregulated in epithelial cells. In situ analyses reveal that macrophages and dendritic cells stain positive for IDO, but that most of the IDO(+) cells were a novel population of CD3(+)CD4(+)IDO(+) cells. The proportion of CD4(+)IDO(+) T cells was significantly higher in patients with moderate GVHD. In situ regulatory T cell and Th17 numbers correlated with overall severity. Although needing confirmatory results from larger sample sets, these data are consistent with the hypothesis that IDO is involved in regulating gastrointestinal GVHD.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835147      PMCID: PMC3565565          DOI: 10.1016/j.bbmt.2011.08.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  17 in total

1.  A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Authors:  Isao Tawara; Warren D Shlomchik; Angela Jones; Weiping Zou; Evelyn Nieves; Chen Liu; Tomomi Toubai; Raimon Duran-Struuck; Yaping Sun; Shawn G Clouthier; Rebecca Evers; Kathleen P Lowler; Robert B Levy; Pavan Reddy
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

2.  Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection.

Authors:  Jacob D Estes; Qingsheng Li; Matthew R Reynolds; Stephen Wietgrefe; Lijie Duan; Timothy Schacker; Louis J Picker; David I Watkins; Jeffrey D Lifson; Cavan Reilly; John Carlis; Ashley T Haase
Journal:  J Infect Dis       Date:  2006-01-30       Impact factor: 5.226

3.  Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance?

Authors:  N K Steckel; U Kuhn; D W Beelen; A H Elmaagacli
Journal:  Scand J Immunol       Date:  2003-02       Impact factor: 3.487

4.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

5.  Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression.

Authors:  Gérard Socié; Jean-Yves Mary; Marc Lemann; Marjan Daneshpouy; Philippe Guardiola; Véronique Meignin; Lionel Ades; Hélène Esperou; Patricia Ribaud; Agnés Devergie; Eliane Gluckman; Jean-Claude Ameisen; Anne Janin
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

6.  The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients.

Authors:  R J Epstein; G B McDonald; G E Sale; H M Shulman; E D Thomas
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

7.  Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality.

Authors:  Lisa K Jasperson; Christoph Bucher; Angela Panoskaltsis-Mortari; Patricia A Taylor; Andrew L Mellor; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113

Review 8.  Creating immune privilege: active local suppression that benefits friends, but protects foes.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

9.  Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy.

Authors:  G E Sale; H M Shulman; G B McDonald; E D Thomas
Journal:  Am J Surg Pathol       Date:  1979-08       Impact factor: 6.394

Review 10.  The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology.

Authors:  Antonio Curti; Sara Trabanelli; Valentina Salvestrini; Michele Baccarani; Roberto M Lemoli
Journal:  Blood       Date:  2008-11-20       Impact factor: 22.113

View more
  7 in total

Review 1.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

2.  Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Authors:  Shernan G Holtan; Ashraf Shabaneh; Brian C Betts; Armin Rashidi; Margaret L MacMillan; Celalletin Ustun; Khalid Amin; Byron P Vaughn; Justin Howard; Alexander Khoruts; Mukta Arora; Todd E DeFor; Darrell Johnson; Bruce R Blazar; Daniel J Weisdorf; Jinhua Wang
Journal:  JCI Insight       Date:  2019-08-08

Review 3.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

Review 4.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

5.  Thiol/redox metabolomic profiling implicates GSH dysregulation in early experimental graft versus host disease (GVHD).

Authors:  Jung H Suh; Bindu Kanathezhath; Swapna Shenvi; Hua Guo; Alicia Zhou; Anureet Tiwana; Frans Kuypers; Bruce N Ames; Mark C Walters
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

6.  miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.

Authors:  Xiao-Su Zhao; Yi-Nuo Wang; Meng Lv; Yuan Kong; Hong-Xue Luo; Xiao-Yang Ye; Qi Wu; Tong-Feng Zhao; Yue-Huan Hu; Hong-Yu Zhang; Ming-Rui Huo; Jun Wan; Xiao-Jun Huang
Journal:  Oncotarget       Date:  2016-07-26

7.  Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites.

Authors:  David Michonneau; Eleonora Latis; Emmanuel Curis; Laetitia Dubouchet; Sivapriya Ramamoorthy; Brian Ingram; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontbrune; Sylvie Chevret; Lars Rogge; Gérard Socié
Journal:  Nat Commun       Date:  2019-12-13       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.